Taha Bali, MD
Addiction Medicine · Boston, MANPI 1093967283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 29.5% of the total. Reporting peaked in 2019 at $318 and has fallen 65.9% since, to $108 in 2024.
Across 21 payments — averaging $31.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$193
- AstraZeneca$133
- Sarepta Therapeutics, Inc.$75
- Sunovion Pharmaceuticals Inc.$68
- UCB, Inc.$49
- CSL Behring$39
- plus $97 from 5 others
What the payments were for
- Food & beverage$655100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 6 | $193 |
| AstraZeneca(2 entities) | 2 | $133 |
| Sarepta Therapeutics, Inc. | 1 | $75 |
| Sunovion Pharmaceuticals Inc. | 3 | $68 |
| UCB, Inc. | 2 | $49 |
| CSL Behring | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Pfizer | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Shire North American Group Inc | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$655 in reported general payments places this provider in the 70th percentile of 57 addiction medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 28 | $3,119 |
| Gabapentin | 222 | $2,633 |
| Azathioprine | 17 | $1,227 |
| Pregabalin | 72 | $781 |
| Duloxetine Hcl | 28 | $575 |
| Propranolol Hcl | 12 | $415 |
| Donepezil Hcl | 29 | $414 |
| Levetiracetam | 13 | $410 |
| Nortriptyline Hcl | 33 | $354 |
| Memantine Hcl | 11 | $312 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 26 | $286 |
| Prednisone | 47 | $196 |
| Divalproex Sodium | 12 | $166 |
| Indomethacin | 12 | $63 |
| Topiramate | 25 | $57 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Boston
- Alysse WurcelBoston$3K
- Modar SukkariehBoston$364
- Evan GaleBoston$70
- Theodore WeatherwaxBoston$32
- Alyssa PeterkinBoston$0
- Miriam KomaromyBoston$0
- Michael BiererBoston$0
- Brian OconnorWoburn$51K
- Laura KehoeAttleboro$35K
- Adam BiedReading$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.